Telitacicept ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 48 | Primary antiphospholipid syndrome | 1 |
| 49 | Systemic lupus erythematosus | 1 |
48. Primary antiphospholipid syndrome
Clinical trials : 4 / Drugs : 5 - (DrugBank : 3) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05078710 (ClinicalTrials.gov) | July 1, 2021 | 24/9/2021 | Telitacicept in Primary APS Patients | A Pilot Study of Telitacicept Treatment in Primary APS Patients | Anti Phospholipid Syndrome | Drug: Telitacicept | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | China |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05247203 (ClinicalTrials.gov) | April 2022 | 26/1/2022 | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus | A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Biological: Telitacicept;Drug: standard therapy | RemeGen Co., Ltd. | NULL | Not yet recruiting | 18 Years | 65 Years | All | 75 | Phase 1 | China |